Nature Communications (Oct 2018)
Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer
- Feng Chen,
- Kai Ma,
- Brian Madajewski,
- Li Zhuang,
- Li Zhang,
- Keith Rickert,
- Marcello Marelli,
- Barney Yoo,
- Melik Z. Turker,
- Michael Overholtzer,
- Thomas P. Quinn,
- Mithat Gonen,
- Pat Zanzonico,
- Anthony Tuesca,
- Michael A. Bowen,
- Larry Norton,
- J. Anand Subramony,
- Ulrich Wiesner,
- Michelle S. Bradbury
Affiliations
- Feng Chen
- Department of Radiology, Sloan Kettering Institute for Cancer Research
- Kai Ma
- Department of Materials Science & Engineering, Cornell University
- Brian Madajewski
- Department of Radiology, Sloan Kettering Institute for Cancer Research
- Li Zhuang
- MedImmune, LLC
- Li Zhang
- Department of Radiology, Sloan Kettering Institute for Cancer Research
- Keith Rickert
- MedImmune, LLC
- Marcello Marelli
- MedImmune, LLC
- Barney Yoo
- Department of Radiology, Sloan Kettering Institute for Cancer Research
- Melik Z. Turker
- Department of Materials Science & Engineering, Cornell University
- Michael Overholtzer
- Cell Biology Program, Sloan Kettering Institute for Cancer Research
- Thomas P. Quinn
- Department of Biochemistry, University of Missouri
- Mithat Gonen
- Department of Epidemiology and Biostatistics, Sloan Kettering Institute for Cancer Research
- Pat Zanzonico
- Department of Medical Physics, Sloan Kettering Institute for Cancer Research
- Anthony Tuesca
- MedImmune, LLC
- Michael A. Bowen
- MedImmune, LLC
- Larry Norton
- Department of Medicine & Office of the President, Memorial Sloan Kettering Cancer Center
- J. Anand Subramony
- MedImmune, LLC
- Ulrich Wiesner
- Department of Materials Science & Engineering, Cornell University
- Michelle S. Bradbury
- Department of Radiology, Sloan Kettering Institute for Cancer Research
- DOI
- https://doi.org/10.1038/s41467-018-06271-5
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 11
Abstract
One of the major obstacles in nanoparticle-based therapy is to achieve tumour targeting, limiting non-specific accumulation of the nanoparticles. Here the authors propose the conjugation of anti-HER2 scFv fragments to the silica nanoparticles, increasing specificity and limiting the final size of the immunoconjugates below the renal clearance threshold.
